SLC39A6 (also known as ZIP6) encodes a zinc transporter protein belonging to the ZIP (Zrt-, Irt-like Protein) family, a group of proteins critical for cellular zinc homeostasis. Zinc is an essential trace element serving as a catalytic cofactor for over 300 enzymes and a structural component of numerous proteins. In the brain, zinc plays crucial roles in synaptic transmission, neuronal signaling, and protection against oxidative stress. The SLC39A6 protein facilitates zinc uptake into cells, contributing to intracellular zinc balance and serving as a key component of the metallostasis network that maintains zinc homeostasis in the central nervous system. [1]
Dysregulation of zinc homeostasis is increasingly recognized as a contributing factor in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). SLC39A6 and related zinc transporters are emerging as important players in these disease processes, with implications for understanding disease mechanisms and developing therapeutic interventions. [2]
The ZIP family transporters, including SLC39A6, are characterized by several structural features:
SLC39A6 is a member of the LIV-1 subfamily of ZIP transporters, named after the breast cancer marker "LIV-1" (Leukemia Virus-Integrase 1). This subfamily is characterized by additional sequence features and is often associated with epithelial-mesenchymal transition and cellular migration. [3]
ZIP transporters operate as symporters, transporting zinc ions along with bicarbonate ions into the cytoplasm. The transport process involves:
The bicarbonate co-transport distinguishes ZIP transporters from ZnT (SLC30) family transporters, which function as antiporters. This mechanism allows cells to accumulate zinc against concentration gradients. [1:1]
In the nervous system, SLC39A6 participates in several critical functions:
SLC39A6 exhibits region-specific expression in the brain:
Cell-type specificity:
ZIP6 expression is developmentally regulated:
Zinc dyshomeostasis is a well-documented feature of Alzheimer's disease pathology:
Amyloid-beta interactions: Zn²⁺ binds to amyloid-beta peptides, promoting aggregation and plaque formation. The Zn²⁺-Aβ complex is more neurotoxic than Aβ alone, and zinc homeostasis disruption may accelerate amyloid pathology. [4]
Tau pathology: Zinc influences tau phosphorylation through direct effects on kinases and phosphatases. Altered zinc transport may contribute to tau hyperphosphorylation and neurofibrillary tangle formation.
Synaptic zinc dysregulation: Synaptic Zn²⁺ handling is impaired in AD, affecting NMDA receptor function and synaptic plasticity. Zinc-dependent AMPA receptor trafficking is altered, contributing to memory deficits. [5]
Oxidative stress: Zinc deficiency compromises antioxidant defenses, while zinc redistribution triggers oxidative stress. The balance between intracellular and extracellular zinc is critical for neuronal survival. [6]
Metal-protein interaction hypothesis: Zinc, along with copper and iron, may contribute to oxidative damage through metal-catalyzed oxidation reactions in AD brains.
SLC39A6 expression alterations have been reported in AD brain tissue, though the specific changes and their functional significance continue to be investigated. The transporter may represent both a biomarker of zinc dyshomeostasis and a potential therapeutic target. [7]
Zinc homeostasis is increasingly implicated in PD pathogenesis:
Substantia nigra vulnerability: Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable to zinc dysregulation due to their high metabolic demands and calcium handling properties.
α-Synuclein interactions: Zinc can accelerate α-synuclein aggregation and influence its cellular distribution. Altered zinc transport may affect the aggregation and toxicity of this protein.
Mitochondrial dysfunction: Zinc plays roles in mitochondrial function and antioxidant defense. Disrupted zinc homeostasis may exacerbate mitochondrial impairment in PD.
Neuroinflammation: Zinc modulates microglial activation and neuroinflammatory responses. Altered zinc transport may contribute to chronic neuroinflammation in PD.
Protein homeostasis impairment: The autophagy-lysosome system, crucial for protein clearance, is zinc-sensitive. Zinc dysregulation may impair protein quality control mechanisms.
SLC39A6 interfaces with multiple zinc-dependent cellular processes:
SLC39A6 expression is regulated by:
Targeting zinc homeostasis represents a promising therapeutic approach:
Several challenges complicate zinc-based therapies:
Liuzzi JP, Cousins RJ. Zinc transporters, ZnT and ZIP gene families. Biochim Biophys Acta. 2004. ↩︎ ↩︎
Kagaga Y, et al. Zinc transporters and their role in the brain. J Neurol Sci. 2012. ↩︎
Sensel J, et al. Identification and characterization of a new zinc transporter gene, ZIP-6. J Recept Signal Transduct Res. 2001. ↩︎
Ayton S, et al. Synaptic Zn2+ homeostasis and its significance in Alzheimer's disease. Brain Res Bull. 2013. ↩︎
Lichter K, et al. ZIP10 regulates AMPA receptor trafficking in hippocampal neurons. J Biol Chem. 2017. ↩︎
Adlard PA, et al. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. J Neural Transm. 2015. ↩︎
Dev S, et al. Zinc dyshomeostasis in Alzheimer's disease. J Alzheimer's Dis. 2021. ↩︎
O'Neill CA, et al. Zinc in the aging brain. Front Aging Neurosci. 2013. ↩︎